Effects of postoperative cyclosporine ophthalmic emulsion 0.05% (Restasis) following glaucoma surgery

Clinical and Experimental Ophthalmology

Volumn 37, Issue 9, 2009, Pages 842-848

  Fakhraie, Ghasem ^a   Lopes, Joao F ^a   Spaeth, George L ^a   Almodin, Juliana ^a   Ichhpujani, Parul ^a   Moster, Marlene R ^a  

^a WILLS EYE HOSPITAL   (United States)

Author keywords

Conjunctiva; Cyclosporine A; Inflammation; Trabeculectomy

Indexed keywords

ARTIFICIAL TEAR; CYCLOSPORIN A;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRY EYE; EYE PAIN; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; NEOVASCULAR GLAUCOMA; OPEN ANGLE GLAUCOMA; PHACOEMULSIFICATION; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; SCHIRMER TEST; TRABECULECTOMY; VISUAL ACUITY;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; BLISTER; CONJUNCTIVA; CYCLOSPORINE; DOUBLE-BLIND METHOD; FEMALE; GLAUCOMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TIME FACTORS; TRABECULECTOMY;

EID: 73649123557     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2009.02134.x     Document Type: Article

References (24)

1. Yoon PS, Singh K. Update on antifibrotic use in glaucoma surgery, including use in trabeculectomy and glaucoma drainage implants and combined cataract and glaucoma surgery. Curr Opin Ophthalmol 2004, 15:141-6.
2. Turacli ME, Gunduz K, Aktan G, Sencer H. Topical cyclosporine as a possible new antimetabolite in trabeculectomy. Ophthalmic Surg Lasers 1996, 27:438-44.
3. Turacli E, Gunduz K, Aktan G, Tamer C. A comparative clinical trial of mitomycin C and cyclosporin A in trabeculectomy. Eur J Ophthalmol 1996, 6:398-401.
4. Johnsson C, Gerdin B, Tufveson G. Effects of commonly used immunosuppressants on graft-derived fibroblasts. Clin Exp Immunol 2004, 136:405-12.
5. Perry HD, Doshi SJ, Donnenfeld ED, Bai GS. Topical cyclosporin A in the management of therapeutic keratoplasty for mycotic keratitis. Cornea 2002, 21:161-3.
6. Perry HD, Donnenfeld ED. Dry eye diagnosis and management in 2004. Curr Opin Ophthalmol 2004, 15:299-304.
7. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000, 107:631-9.
8. Inoue K, Amano S, Kimura C. Long-term effects of topical Cyclosporine A treatment after penetrating keratoplasty. Jpn J Ophthalmol 2000, 44:302-5.
9. Stevenson D, Tauber J, Reis BL. Efficacy and safety of Cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 2000, 107:967-74.
10. Knagenhjelm SK, Froyland K, Ringvold A. Toxicological evaluation of cyclosporine eyedrops. Acta Ophthalmol Scand 1999, 77:200-3.
11. Cristofanilli M, Pescosolido N, Risuleo G, Scarsella G. A murine cell culture model for post-trabeculectomy anfibrotic treatment: induction of apoptosis by cyclosporin. Acta Ophthalmol Scand 2001, 79:309-12.
12. Schiffman RM, Christianson MD, Jacobsen G. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol 2000, 118:615-21.
13. Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: a 25-year review. Cornea 2000, 19:644-9.
14. Stewart WC, Kolker AE, Stewart JA. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol 2003, 135:314-20.
15. Cantor LB, Mantravadi A, WuDunn D. Morphologic classification of filtering blebs after glaucoma filtration surgery: the Indiana Bleb Appearance Grading Scale. J Glaucoma 2003, 12:266-71.
16. Lattanzio FA, Crouch ER, Mitrev PV. Cyclosporin as an adjunct to glaucoma filtration surgery. J Glaucoma 2005, 14:441-7.
17. Kuppens EV, van Best JA, Sterk CC, de Keizer RJ. Decreased basal tear turnover in patients with untreated primary open-angle glaucoma. Am J Ophthalmol 1995, 120:41-6.
18. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmology 2002, 86:418-23.
19. Yenice O, Temel A, Orum O. The effect of artificial tear administration on visual field testing in patients with glaucoma and dry eye. Eye 2007, 21:214-17.
20. Feiner L, Piltz-Seymour JR. Collaborative Initial Glaucoma Treatment Study. Collaborative Initial Glaucoma Treatment Study: a summary of results to date. Curr Opin Ophthalmol 2003, 14:106-11.
21. Janz NK, Wren PA, Lichter PR. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology 2001, 108:1954-65.
22. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol 1994, 112:1437-45.
23. Herreras JM, Pastor JC, Calonge M, Asensio VM. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology 1992, 99:1082-8.
24. Yalvac IS, Gedikolu G, Karagoz Y. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand 1995, 73:246-8.